Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure.

Ryan, K E

Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. [electronic resource] - Thrombosis and haemostasis Nov 1992 - 563-9 p. digital

Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0340-6245


Adult
Aged
Aged, 80 and over
Antithrombin III--metabolism
Blood Coagulation--drug effects
Dermatan Sulfate--administration & dosage
Dose-Response Relationship, Drug
Female
Fibrinolytic Agents--therapeutic use
Fibrinopeptide A--metabolism
Heparin--therapeutic use
Humans
Kidney Failure, Chronic--blood
Male
Middle Aged
Peptide Hydrolases--metabolism
Renal Dialysis
Thrombosis--prevention & control